Shlomo A Koyfman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3484859/publications.pdf

Version: 2024-02-01

249298 150775 3,766 97 26 citations h-index papers

g-index 97 97 97 5474 docs citations times ranked citing authors all docs

59

#	Article	IF	CITATIONS
1	Higher metastasis and death rates in cutaneous squamous cell carcinomas with lymphovascular invasion. Journal of the American Academy of Dermatology, 2022, 86, 766-773.	0.6	6
2	Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology, 2022, 18, 833-847.	1.1	22
3	Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes. Journal of the American Academy of Dermatology, 2022, 86, 1301-1308.	0.6	3
4	Nasopharyngeal cancer: Incidence and prognosis of human papillomavirus and Epstein–Barr virus association at a single North American institution. Head and Neck, 2022, 44, 851-861.	0.9	8
5	Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel. Oncologist, 2022, 27, 4-6.	1.9	4
6	Outcomes After Oral Cavity and Oropharyngeal Salvage Surgery. Laryngoscope, 2022, 132, 1984-1992.	1.1	2
7	Implications of Satellitosis or In-transit Metastasis in Cutaneous Squamous Cell Carcinoma. JAMA Dermatology, 2022, 158, 390.	2.0	9
8	Your First Shot Is Your Best Shot. International Journal of Radiation Oncology Biology Physics, 2022, 112, 852.	0.4	0
9	Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. Journal of the American Academy of Dermatology, 2022, 87, 87-94.	0.6	14
10	Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative study. Oral Oncology, 2022, 126, 105781.	0.8	3
11	Variability in Depth of Invasion Measurements in Carcinomas of the Oral Cavity and the Effect on Pathologic Tumor Staging. Head and Neck Pathology, 2022, 16, 963-968.	1.3	2
12	Performance of the Neck Imaging Reporting and Data System as applied by general neuroradiologists to predict recurrence of head and neck cancers. Head and Neck, 2022, 44, 2257-2264.	0.9	3
13	Noncompliance with surgical margin guidelines is associated with histologic margin positivity: A retrospective case-control study. Journal of the American Academy of Dermatology, 2021, 84, 1126-1128.	0.6	O
14	Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design. Oral Oncology, 2021, 112, 105046.	0.8	11
15	Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit Metastasis. Anticancer Research, 2021, 41, 289-295.	0.5	8
16	A Systematic Review of Primary, Adjuvant, and Salvage Radiation Therapy for Cutaneous Squamous Cell Carcinoma. Dermatologic Surgery, 2021, 47, 587-592.	0.4	8
17	Failure rate in the untreated contralateral node negative neck of small lateralized oral cavity cancers: A multi-institutional collaborative study. Oral Oncology, 2021, 115, 105190.	0.8	6
18	Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration. Current Oncology, 2021, 28, 2409-2419.	0.9	8

#	Article	IF	CITATIONS
19	Adjuvant therapy for h <scp>ighâ€risk</scp> cutaneous squamous cell carcinoma: <scp>10â€year</scp> review. Head and Neck, 2021, 43, 2822-2843.	0.9	13
20	In vivo assessment of the safety of standard fractionation Temporally Feathered Radiation Therapy (TFRT) for head and neck squamous cell carcinoma: An R-IDEAL Stage 1/2a first-in-humans/feasibility demonstration of new technology implementation. Radiotherapy and Oncology, 2021, 163, 39-45.	0.3	5
21	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innovations, 2021, 1, 100045.	1.2	5
22	Dosimetric Benefits of Omitting Primary Tumor Beds in Postoperative Radiotherapy After Transoral Robotic Surgery Using the Auto-Planning Technique. Cureus, 2021, 13, e18065.	0.2	1
23	Radiomic Features Associated With HPV Status on Pretreatment Computed Tomography in Oropharyngeal Squamous Cell Carcinoma Inform Clinical Prognosis. Frontiers in Oncology, 2021, 11, 744250.	1.3	16
24	Updated Outcomes of Split Course Radiotherapy in Elderly or Infirm Patients With Advanced Cancers of the Head and Neck. Anticancer Research, 2021, 41, 4995-5000.	0.5	1
25	Incidence and outcomes of cutaneous angiosarcoma: A SEER population-based study. Journal of the American Academy of Dermatology, 2020, 83, 809-816.	0.6	30
26	Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins. Journal of the American Academy of Dermatology, 2020, 82, 420-429.	0.6	23
27	Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy. Laryngoscope, 2020, 130, 2372-2377.	1.1	7
28	Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision. Journal of the American Academy of Dermatology, 2020, 82, 1195-1204.	0.6	25
29	Impact of active smoking on outcomes in HPV+ oropharyngeal cancer. Head and Neck, 2020, 42, 269-280.	0.9	19
30	Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging. Oral Oncology, 2020, 111, 105030.	0.8	7
31	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiotherapy and Oncology, 2020, 151, 314-321.	0.3	24
32	Continuous infusion chemotherapy, radiotherapy, and FDGâ€PET are feasible during extracorporeal membrane oxygenation. Pediatric Blood and Cancer, 2020, 67, e28429.	0.8	7
33	Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary Origin. Anticancer Research, 2020, 40, 4207-4214.	0.5	11
34	The American Brachytherapy society consensus statement for skin brachytherapy. Brachytherapy, 2020, 19, 415-426.	0.2	28
35	A Distinctive Lineage-Negative Cell Population Produces IL-17A in Cutaneous Squamous Cell Carcinoma. Journal of Interferon and Cytokine Research, 2020, 40, 418-424.	0.5	2
36	Technical Note: A stepâ€byâ€step guide to Temporally Feathered Radiation Therapy planning for head and neck cancer. Journal of Applied Clinical Medical Physics, 2020, 21, 209-215.	0.8	5

3

#	Article	IF	CITATIONS
37	Rethinking the 10â€packâ€year rule for favorable human papillomavirus–associated oropharynx carcinoma: A multiâ€institution analysis. Cancer, 2020, 126, 2784-2790.	2.0	9
38	Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer. Oral Oncology, 2020, 103, 104585.	0.8	8
39	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.4	156
40	Case Report: Primary Orbital Squamous Cell Carcinoma. Ocular Oncology and Pathology, 2019, 5, 60-65.	0.5	9
41	Surgery and Salvage Limited-Field Irradiation for Control of Cutaneous Squamous Cell Carcinoma With Microscopic Residual Disease. JAMA Dermatology, 2019, 155, 1193.	2.0	7
42	Evaluation of autoâ€planning in IMRT and VMAT for head and neck cancer. Journal of Applied Clinical Medical Physics, 2019, 20, 39-47.	0.8	24
43	The prognostic impact of level I lymph node involvement in oropharyngeal squamous cell carcinoma. Head and Neck, 2019, 41, 3895-3905.	0.9	1
44	Reply to "Rational Radiotherapy: The Role in Node-negative Squamous Cell Carcinoma― Journal of the American Academy of Dermatology, 2019, , .	0.6	0
45	Correlation between plan quality improvements and reduced acute dysphagia and xerostomia in the definitive treatment of oropharyngeal squamous cell carcinoma. Head and Neck, 2019, 41, 1096-1103.	0.9	9
46	Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. JAMA Dermatology, 2019, 155, 442.	2.0	27
47	A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck. Oral Oncology, 2019, 90, 80-86.	0.8	26
48	Reply to C. Schilling et al. Journal of Oncology Practice, 2019, 15, 561-561.	2.5	0
49	IL-17R–EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells. Journal of Experimental Medicine, 2019, 216, 195-214.	4.2	82
50	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG) Tj ETQq	0 0 <u>0 g</u> gBT	/Overlock 10
51	Selectively sparing the submandibular gland when level Ib lymph nodes are included in the radiation target volume: An initial safety analysis of a novel planning objective. Oral Oncology, 2019, 89, 79-83.	0.8	9
52	Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. International Journal of Radiation Oncology Biology Physics, 2018, 100, 606-617.	0.4	68
53	Increased pathologic upstaging with rising time to treatment initiation for head and neck cancer: A mechanism for increased mortality. Cancer, 2018, 124, 1400-1414.	2.0	45
54	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 595-605.	0.4	101

#	Article	IF	CITATIONS
55	Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. International Journal of Radiation Oncology Biology Physics, 2018, 100, 586-594.	0.4	105
56	A matched comparison of human papillomavirus–induced squamous cancer of unknown primary with early oropharynx cancer. Laryngoscope, 2018, 128, 1379-1385.	1.1	13
57	Elucidation of salvage laryngectomy pathologic and clinical variables to guide further treatment intensification investigation. Laryngoscope, 2018, 128, 823-830.	1.1	17
58	Personalizing Postoperative Treatment of Head and Neck Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 515-522.	1.8	22
59	Suboptimal Outcomes in Cutaneous Squamous Cell Cancer of the Head and Neck with Nodal Metastases. Anticancer Research, 2018, 38, 5825-5830.	0.5	27
60	Physician Leadership Development: A Pilot Program for Radiation Oncology Residents. International Journal of Radiation Oncology Biology Physics, 2018, 102, 254-256.	0.4	14
61	Temporally feathered intensityâ€modulated radiation therapy: A planning technique to reduce normal tissue toxicity. Medical Physics, 2018, 45, 3466-3474.	1.6	24
62	Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. Npj Precision Oncology, 2018, 2, 14.	2.3	22
63	In Reply to Yildirim and Topkan. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1273-1274.	0.4	0
64	Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity. Anticancer Research, 2018, 38, 3543-3549.	0.5	16
65	Predictors of distant metastasis in human papillomavirus–associated oropharyngeal cancer. Head and Neck, 2017, 39, 940-946.	0.9	31
66	A multiâ€institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer, 2017, 123, 2054-2060.	2.0	115
67	Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. Future Oncology, 2017, 13, 603-613.	1.1	31
68	Clinical Research Ethics: Considerations for the Radiation Oncologist. International Journal of Radiation Oncology Biology Physics, 2017, 99, 259-264.	0.4	8
69	Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 98, 784-792.	0.4	25
70	Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancerâ [†] . Oral Oncology, 2017, 74, 49-55.	0.8	37
71	Program director and chief resident perspectives on the educational environment of US radiation oncology programs. Practical Radiation Oncology, 2017, 7, e65-e70.	1.1	6
72	Impaired vocal cord mobility in T2NO glottic carcinoma: Suboptimal local control with Radiation alone. Head and Neck, 2016, 38, 1832-1836.	0.9	26

#	Article	IF	CITATIONS
73	Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11. Oral Oncology, 2016, 57, 21-26.	0.8	28
74	Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: A National Cancer Data Base analysis. Cancer, 2016, 122, 3472-3483.	2.0	37
75	Transoral robotic surgery: The radiation oncologist's perspective. Oral Oncology, 2016, 60, 96-102.	0.8	25
76	Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 1164.	1.2	20
77	The prognostic value of pretreatment FDG-PET parameters in HPV-associated oropharynx cancer. Journal of Radiation Oncology, 2016, 5, 161-167.	0.7	1
78	Informed consent conversations and documents: A quantitative comparison. Cancer, 2016, 122, 464-469.	2.0	35
79	Regional control is preserved after dose de-escalated radiotherapy to involved lymph nodes in HPV positive oropharyngeal cancer. Oral Oncology, 2016, 53, 91-96.	0.8	10
80	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncology, The, 2016, 17, 440-451.	5.1	607
81	Periocular Skin Cancer in Solid Organ Transplant Recipients. Ophthalmology, 2016, 123, 203-208.	2.5	10
82	Impact of feeding tube choice on severe late dysphagia after definitive chemoradiotherapy for human papillomavirus–negative head and neck cancer. Head and Neck, 2016, 38, E1054-60.	0.9	21
83	Risk Factors Associated with Disease Recurrence in Patients with Stage III/IV Squamous Cell Carcinoma of the Oral Cavity Treated with Surgery and Postoperative Radiotherapy. Anticancer Research, 2016, 36, 785-92.	0.5	16
84	Stereotactic body radiotherapy for a large arteriovenous malformation of the head and neck. Laryngoscope, 2015, 125, 379-382.	1.1	8
85	Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. Journal of the American Academy of Dermatology, 2015, 73, 221-227.	0.6	64
86	Effect of Human Papillomavirus on Patterns of Distant Metastatic Failure in Oropharyngeal Squamous Cell Carcinoma Treated With Chemoradiotherapy. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 457.	1.2	104
87	Carotid blowout in a patient with nasopharyngeal carcinoma treated with SBRT re-irradiation for local recurrence using twice weekly treatment. Journal of Radiosurgery and SBRT, 2015, 3, 325-329.	0.2	1
88	Early and Severe Radiation Toxicity Associated with Concurrent Sirolimus in an Organ Transplant Recipient with Head and Neck Cutaneous Squamous Cell Carcinoma: A Case Report. Anticancer Research, 2015, 35, 5511-4.	0.5	5
89	Endoscopic and Open Surgical Approaches to Locally Advanced Sinonasal Melanoma. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 840.	1.2	49
90	Repeat stereotactic body radiotherapy for recurrent spinal tumors is feasible with accurate assessment of cumulative spinal cord dose. Journal of Radiation Oncology, 2014, 3, 185-193.	0.7	1

#	Article	IF	CITATIONS
91	Consent Form Heterogeneity in Cancer Trials: The Cooperative Group and Institutional Review Board Gap. Journal of the National Cancer Institute, 2013, 105, 947-953.	3.0	17
92	Marginal Recurrence Requiring Salvage Radiotherapy After Stereotactic Body Radiotherapy for Spinal Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 83, 297-302.	0.4	53
93	Enteral Feeding Tubes in Patients Undergoing Definitive Chemoradiation Therapy for Head-and-Neck Cancer: AÂCritical Review. International Journal of Radiation Oncology Biology Physics, 2012, 84, 581-589.	0.4	77
94	The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Practical Radiation Oncology, 2012, 2, e95-e100.	1.1	41
95	Stereotactic Radiosurgery for Single Brainstem Metastases: The Cleveland Clinic Experience. International Journal of Radiation Oncology Biology Physics, 2010, 78, 409-414.	0.4	62
96	A consent form template for phase I oncology trials. IRB: Ethics & Human Research, 2009, 31, 1-8.	0.8	86
97	Risks and benefits associated with novel phase 1 oncology trial designs. Cancer, 2007, 110, 1115-1124.	2.0	43